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LETTER TO THE EDITOR

Monkeypox outbreak in the age
of COVID‑19: a new global health emergency
Rahim Hirani1* , Dawood Rashid1, Joshua Lewis1, Rasheed Hosein‑Woodley1 and Ali Issani2

Keywords: Monkeypox virus, Coronavirus disease 2019 (COVID-19), Global health
Dear Editor,
The World Health Organization recently declared monkeypox as a global emergency after reporting more than
57,000 new cases worldwide [1]. Monkeypox is an orthopoxvirus similar in nature to the Variola virus, which is
a causative agent for smallpox [2]. Monkeypox virus presents as a unique challenge for global health and should
be regarded with grave concern as the vast majority of
cases are occurring in countries where the disease is not
considered endemic. Furthermore, the spread of this
pathogen is occurring concomitantly as the world is still
engaged in a battle with the coronavirus disease 2019
(COVID-19) pandemic, which has caused substantial
damage to global healthcare infrastructure. If monkeypox continues its rapid spread, hospitals could be quickly
overwhelmed by both COVID-19 and monkeypox cases.
Now more than ever, early symptom recognition and use
of all available treatments to contain monkeypox outbreaks are vital. Early precautions including early recognition of symptoms by physicians, use of currently
available treatments, and promoting precautionary measures in at-risk populations may be vital in preventing
hospital burden and further physician burnout.
The effects of COVID-19 have reverberated throughout a multitude of communities across the world. People
have been profoundly affected, especially that of frontline workers such as clinicians. A surge in emergency
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room visits coupled with a disease that at the time had no
real cure, substantially increased the workload on healthcare workers [3]. This led to a surge in burnout and mental health conditions due to increased stress, depression,
and anxiety. Likewise, it also caused an increase in suicide rates amongst physicians. While their services were
the need of the hour, especially during the peak of the
pandemic, their own health could have affected how they
treat their patients, resulting in unintentional suboptimal care. We argue that this recent monkeypox outbreak
could exacerbate these effects and further overwhelm our
healthcare workers if precautions are not taken in time.
Whilst combating the psychological burden associated
with the treatment of diseases such as COVID-19 and
monkeypox poses a systemic challenge for institutions
and will likely be a long-term effort—the clinical component also presents a uniquely challenging perspective.
Currently, no standard treatment exists for management
of monkeypox infections. Clinical trials are being created to test the efficacy of the antiviral drug tecovirimat
in clade 3 monkeypox infections in humans. Tecovirimat has previously been approved in accordance with
the Food and Drug Administration (FDA) Animal Rule
for treatment of smallpox, by using non-human primates
infected with monkeypox as a model for smallpox [4].
As the only FDA approved treatment for smallpox, the
Centers for Disease Control and Prevention (CDC) has
allowed clinical use of tecovirimat under expanded access
protocol. Although animal models do not always confer efficacy in humans, three early case studies in Massachusetts, using 600 mg tecovirimat twice daily, have
shown promising early results. In all three cases, there
was symptom improvement after initiation of tecovirimat
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therapy with two cases showing a halt in progression of
skin lesions within 2–4 d of treatment [5]. A retrospective cohort study done in the UK by Adler et al. [6] for the
cases between 2018 and 2021 that examined both tecovirimat (600 mg twice daily) and brincidofovir (200 mg
weekly for three weeks) had similar findings. One patient
treated with 600 mg tecovirimat twice daily developed
no new lesions 24 h after initiation of therapy with blood
and upper respiratory samples being polymerase chain
reaction (PCR) negative after 48 h. In the three patients
treated with brincidofovir, there was some reduction
in monkeypox viral PCR cycle threshold, but improvements were not consistent between the three patients.
In addition, all three patients developed elevated alanine transaminase levels and therapy was discontinued
early. Although available data is currently limited, early
case studies demonstrate the efficacy and safety of tecovirimat as the best available treatment for monkeypox.
Because it will take time for clinical trials for tecovirimat
to be approved and completed, treatment under the CDC
expanded access protocol may be vital for containing the
virus and preventing further burden on global healthcare
systems.
Furthermore, the CDC recommends two vaccination
protocols for gaining immunization towards monkeypox. In 2015, the ACAM2000 vaccine was approved for
immunization towards orthopoxvirus, specifically that of
smallpox. The ACAM2000 is a live, attenuated virus that
carries vaccinia virus which belongs to the same family
of viruses such as monkeypox. However, in 2021 it was
voted by the Advisory Committee on Immunization
Practices that the JYNNEOS vaccine offers greater preexposure protection than the ACAM2000 vaccination
and as such should be used as the gold standard for treatment for the foreseeable future. Additionally, it has been
shown that the ACAM2000 vaccine can lead to greater
side-effects compared with JYNNEOS vaccine especially
in populations who are immunocompromised [7]. With
the availability of two vaccines on the market, it is imperative to engage in public health projects to encourage
groups who are at high-risk for exposure to monkeypox
to procure either of these vaccines.
With the rapid rise in cases of monkeypox, it is crucial
that we utilize an active mode of pedagogy. We must utilize the newfound knowledge to develop early symptom
recognition and treatment strategies, as well as promoting awareness in at-risk populations, which would allow
us to combat this new threat as a community. We must
work collectively in identifying issues that can be exacerbated by the onset of another pandemic and develop an
approach to mitigate those issues.
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